| abstract |
This invention provides defined by the Formula (See Formula) or a pharmaceutically acceptable salt thereof; where R1, Q, Y3, Y4, U5, U6, U8, R2 and R3 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of formula I, or a pharmaceutically acceptable salt thereof; as defined in the specification, together with a pharmaceutically acceptable carrier, diluent or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, which comprises administering to the animal a compound of Formula I or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, which comprises administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, both alone and in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis osteoarthritis and rheumatoid arthritis, arthritis other than osteoarthritis or rheumatoid arthritis, heart failure, inflammatory bowel disease, heart failure, age-related macular degeneration, obstructive pulmonary disease Chronic, asthma, periodontal diseases, psoriasis, atherosclerosis and osteoporosis in a patient, which comprises administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition. The invention also provides combinations comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification. |